Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Four cases of primary malignant melanoma of the vagina in women aged 23, 44, 51 and 65 years are presented. In these 4 cases, thorough clinical and postmortem examinations ruled out the possibility of a primary melanoma elsewhere. The primary tumors showed exophytic growth with superficial ulceration. Three of the melanomas arose from the middle third of the vagina and one from the upper third. Melanin was visible in sections stained with hematoxylin and eosin in 3 of the tumors. In the other one, the first biopsy failed to reveal melanin. However, the second biopsy performed following irradiation showed abundant melanin pigment. Electron microscopic examination of 3 tumors revealed premelanosomes and melanosomes in the tumor cells, thus confirming the diagnosis. Two neoplasms showed atypical histologic features, and only the presence of melanin enabled us to make diagnosis of malignant melanoma. One melanoma was associated with an adjacent widespread intraepithelial component of superficial spreading type indicating its probable mode of origin. All 4 patients died of widespread metastases within 13 months after initial treatment. These 4 cases, in which clinical diagnosis was confirmed by thorough autopsy, strongly indicate that malignant melanoma can arise directly from the vagina.
 ...
PMID:Primary malignant melanoma of the vagina: study of four autopsy cases with ultrastructural findings. 36 16

The leukocyte adherence inhibition (LAI) microassay detects tumor-associated antigen(s). Extracts of colon carcinoma (MCA-38 and B16 melanoma tumors, both syngeneic to the C57BL/6J mice) are recognized only by peritoneal cells from mice bearing the corresponding tumor. To ascertain whether this in vitro antigenic recognition correlates with the ability of the host to recognize and reject a tumor in vivo, serial LAI microassays were performed synchronously with experiments designed to test the ability of mice bearing tumors to reject live secondary tumor challenges. Concomitant tumor immunity was present in the MCA-38 tumor-bearing mice on 3 occasions from 5 to 15 days from primary inoculation. In the B16 system, concomitant immunity was present on one occasion 10 days after primary inoculation. These results in turn were paralleled with the specific in vitro recognition of tumor antigens as detected by the LAI microassays. Loss of immunity in the "eclipse" phase of tumor development, as detected by concomitant tumor immunity, was paralleled by nonreactivity of the indicator cells in the LAI microassay.
 ...
PMID:Correlations between the leukocyte adherence inhibition microassay and in vivo tests of transplantation resistance. 36 84

In the Oncocytological Center of Zala Country were investigated in the recent years 2378 cases from effusions of pleural cavity. Ten of the tested cases had been proved to be metastases of sarcomatous lesions. Three of them were myosarcoma, two of them were malignant melanoma and one fibromyosarcoma, reticulosarcoma, osteosarcoma and sarcomatous stage of Hodgkin disease, each. The author gives a review of the cytological characteristics of metastatic sarcomatous lesions. Up to the opinion of the author there are some characteristics which can help in the typing.
 ...
PMID:[Cytology of metastases of rare tumors in the pleura (author's transl)]. 37 78

Nineteen temporal bones were examined from 11 patients who had metastatic temporal bone disease from a distant primary. The salient clinical features were: the high incidence of occult temporal bone involvement (7 of the 10 clinically documented cases), the considerable incidence of melanoma (3 of 10) and the variable correlation between clinical findings and pathologic localization of tumor in the temporal bone. Pathologic examination revealed two distinct modes of tumor spread within the temporal bone: 1) vascularosseous (petrous apex, mastoid, middle ear, external canal); and 2) perineural (nerves in IAC branches, labyrinthine endorgans). Every case was involved by one or both or these routes and no case of CSF-borne metastasis to the perilymphatic space was seen. The external canal was involved extensively in spite of an intact tympanic membrane. Since the presence of symptomatic or occult metastases in the temporal bone affects treatment and prognosis, they must be actively sought by the clinician.
 ...
PMID:Metastatic tumors in the temporal bone--a pathophysiologic study. 37 58

One hundred twenty patients with metastatic malignant melanoma were randomized to receive either cyclophosphamide, 600 mg/m2 IV, on day 1 plus DTIC 200 mg/m2 IV days 1 through 5, or the same chemotherapy plus C. parvum 5 mg/m2 IV on day 8 and day 15. Therapy was repeated every 21 days. Although responses were observed in 13.8% of patients on cyclophosphamide plus DTIC versus 25.5% of patients on cyclophosphamide plus DTIC plus C. parvum, the median duration of remission was 15.6 weeks on chemotherapy and 13.0 weeks on chemotherapy plus C. parvum. Furthermore, survival was similar on both regimens (6.1 months versus 5.7 months, respectively). Favorable prognostic factors included metastatic disease confined to skin or lymph nodes (33% responses), performance status greater than 70% (24% response rate), and administration of three or more courses of chemotherapy (31% response rate). The dose limiting toxicity was myelosuppression, which was equal on both regimens. Chills and fever were common in response to C. parvum, and, rarely hypotension, cyanosis, or immune nephritis was observed. The addition of C. parvum to chemotherapy with cyclophosphamide plus DTIC is not recommended.
 ...
PMID:Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma. 38 76

Metastatic involvement of the gallbladder in melanoma is rare, but constitutes the most common metastatic lesion involving this organ. Two cases of metastatic melanoma to the gallbladder with radiographic evidence of gallbladder abnormality prior to surgery are presented. These cases are compared to the nine previously reported cases of metastatic melanoma to the gallbladder with abnormal cholecystograms. All eleven cases presented with signs and symptoms compatible with cholecystitis. Nine of the eleven patients had a previous melanoma primary and most had other extrabiliary metastases. Associated cholelithiasis appeared to be only incidental. In addition, nine reported cases of "primary" biliary melanoma were reviewed. Clinical and pathologic presentations in the latter cases were similar to the former cases with metastases. Seventy-eight percent had extrabiliary sites of metastasis at some time in the course of their disease, tending to refute the impression of "primary" biliary melanoma. Melanoma in the gallbladder is much more likely to have metastasized from a regressed skin primary than to have arisen de novo. The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.
 ...
PMID:Metastatic melanoma of the gallbladder. 38 9

Radiologic experience in 67 patients with melanoma metastatic to all portions of the gastrointestinal tract is reviewed. Besides the well known "bull's-eye" lesion of the upper gastrointestinal tract, a large variety of radiologic presentations of melanoma metastases is discussed and illustrated. Because of extended survival due to improved chemotherapy and immunotherapy, the importance of careful radiologic examination of the melanoma patient is stressed.
 ...
PMID:Radiologic spectrum of melanoma metastatic to the gastrointestinal tract. 40 31

BCG immunotherapy often has severe complications in cancer patients despite lack of toxicity in the immunocompetent individual. MER, a cell wall fraction of BCG, has been reported to cause immunopotentiation similar to that of BCG without equivalent toxicity. Recently, animal models have been reported to develop MER complications, especially disseminated granuloma formation, like those of BCG. For the past several years, MER has been used as adjuvant immunotherapy for treatment of malignant tumors with minimal systemic toxicity reported. A patient with malignant melanoma was treated with intralesional MER at the site of local metastases. He developed military pulmonary granulomatosis and a severe cutaneous eruption in association with MER therapy. The toxicities of BCG and MER therapy were compared with the pathogenesis of granuloma formation reviewed. This patient's complications were consistent with a hypersensitivity reaction to MER. Pulmonary granulomatosis and rash must be added to the list of known MER toxicities.
 ...
PMID:Systemic complications of MER immunotherapy of cancer: pulmonary granulomatosis and rash. 42 Nov 77

The writers examined histologically and histochemically the melanomas removed in 40 patients, subjected to general and local hyperthermia associated with radiation and chemotherapy. In such cases it was found that melanoma tissues exhibit grave destructive changes characterized by the morphological features, which are manifested by microcirculatory disorders in the tumor and metastases and are associated with extensive injuries of the neoplastic tissue.
 ...
PMID:["Pathomorphosis" of skin melanomas in the comprehensive treatment using hyperthermia]. 42 93

Experimental data in animal models and clinical experience with a systemic immunotherapeutic approach in patients with tumours were the determining factors in the decision to test the local effect of this form of therapy on primary and secondary malignant lesion of the skin. The antitumour effect of local immunotherapy seems to be based on the induction of a cell-mediated immune challenge reaction in close contact with the malignant neoplasm. A trial of local immunotherapy was undertaken in 30 patients with melanoma with local recurrence of the primary tumour or multiple metastases involving the skin. The therapeutic indications and clinical response are discussed.
 ...
PMID:[Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)]. 42 33


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>